Core Viewpoint - Beijing JianKai Technology Co., Ltd. anticipates significant growth in its 2025 annual performance, with substantial increases in both revenue and net profit compared to the previous year [2][4]. Performance Forecast - The company expects to achieve an operating revenue of approximately 315 million yuan in 2025, representing an increase of 87.90 million yuan, or 38.71%, compared to the previous year [2][4]. - The projected net profit attributable to the parent company is estimated to be between 60 million and 66 million yuan, an increase of 30.16 million to 36.16 million yuan, or 101.09% to 121.20% year-on-year [2][4]. - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be between 45 million and 50 million yuan, reflecting an increase of 25.52 million to 30.52 million yuan, or 131.01% to 156.68% year-on-year [2][4]. Previous Year Performance - In the previous year, the company reported an operating revenue of 227.10 million yuan [6]. - The total profit was 32.67 million yuan, with a net profit attributable to the parent company of 29.84 million yuan, and a net profit after deducting non-recurring gains and losses of 19.48 million yuan [6]. Reasons for Performance Changes - The anticipated growth in 2025 is primarily attributed to increased order revenue from the sales volume of new drug products launched by overseas clients [8].

Group 1 - ShenNan Electric A expects a net profit increase of 584.66%-721.59% year-on-year for 2025 [1] - Te Yi Pharmaceutical anticipates a net profit increase of 241.55%-339.13% year-on-year for 2025 [1] - RunTu Co. forecasts a net profit increase of 181.05%-227.89% year-on-year for 2025 [1] - QingSong Co. projects a net profit increase of 137.73%-201.74% year-on-year for 2025 [1] - RuiSheng Intelligent expects a net profit increase of 112.00%-139.99% year-on-year for 2025 [1] - JianKai Technology anticipates a net profit increase of 101.09%-121.20% year-on-year for 2025 [1] - XingQi Eye Medicine forecasts a net profit increase of 95.82%-121.56% year-on-year for 2025 [1] - RuiChuang MicroNano expects a net profit increase of approximately 93% year-on-year for 2025 [1] - TianHe Co. projects a net profit increase of 84.35%-169.78% year-on-year for 2025 [1] - ZhongYuan Co. anticipates a net profit increase of 80%-105% year-on-year for 2025 [1] - YiDao Information expects a net profit increase of 76.04%-128.85% year-on-year for 2025 [1] - ShengDa Bio forecasts a net profit increase of 69.93%-120.90% year-on-year for 2025 [1] - HuaRui Precision anticipates a net profit increase of 68.29%-86.99% year-on-year for 2025 [1] - FangZheng Technology expects a net profit increase of 67.06%-98.14% year-on-year for 2025 [1] - JinLing Hotel projects a net profit increase of 65.37%-90.93% year-on-year for 2025 [1] - QiangYi Co. anticipates a net profit increase of 57.87%-71.17% year-on-year for 2025 [1] - LangBo Technology expects a net profit increase of 57.58%-66.53% year-on-year for 2025 [1] - HuaFeng Measurement and Control forecasts a net profit increase of 46%-78% year-on-year for 2025 [1] - Zhaoyi Innovation anticipates a net profit increase of approximately 46% year-on-year for 2025 [1] - JieChang Drive expects a net profit increase of 40%-55% year-on-year for 2025 [1] - ShengYuan Environmental Protection projects a net profit increase of 31.79%-59.24% year-on-year for 2025 [1] - GuangHa Communication anticipates a net profit increase of 21.83%-31.31% year-on-year for 2025 [1] - MaiHe Co. expects a net profit increase of 19.58%-54.76% year-on-year for 2025 [1] Group 2 - YiLing Pharmaceutical expects a net profit of 1.2 billion to 1.3 billion yuan for 2025, turning profitable year-on-year [1] - LiYade anticipates a net profit of 300 million to 380 million yuan for 2025, turning profitable year-on-year [1] - SiRuiPu expects a net profit of 165 million to 184 million yuan for 2025, turning profitable year-on-year [1] - DaMing City anticipates a net profit of 140 million to 165 million yuan for 2025, turning profitable year-on-year [1] - DaHeng Technology expects a net profit of 106 million yuan for 2025, turning profitable year-on-year [1] - GuangHua Technology projects a net profit of 85 million to 120 million yuan for 2025, turning profitable year-on-year [1] - BoTeng Co. expects a net profit of 80 million to 105 million yuan for 2025, turning profitable year-on-year [2] - ZhongBing HongJian anticipates a net profit of 34 million to 46 million yuan for 2025, turning profitable year-on-year [2]

Core Viewpoint - The company, JianKai Technology (688356.SH), forecasts a significant increase in net profit for the year 2025, projecting a net profit attributable to shareholders of the parent company between 60 million to 66 million yuan, representing a year-on-year increase of 30.16 million to 36.16 million yuan, or an increase of 101.09% to 121.20% compared to the previous year [1] Financial Performance - The company expects a year-on-year revenue growth of 38.71% for the year 2025 [1] - The net profit attributable to shareholders of the parent company is projected to increase by 101.09% to 121.20% year-on-year [1] - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is expected to increase by 131.01% to 156.68% year-on-year [1] Growth Drivers - The anticipated growth in orders and corresponding profit is primarily driven by the sales ramp-up of products launched by downstream overseas new drug clients [1]

Core Viewpoint - The company expects significant growth in both revenue and net profit for the year 2025, indicating a strong financial outlook and operational performance [1] Financial Performance - The company anticipates achieving an operating revenue of approximately 315 million yuan in 2025, which represents an increase of 87.9 million yuan compared to the previous year, reflecting a year-on-year growth of 38.71% [1] - The projected net profit attributable to the parent company's shareholders is expected to be between 60 million and 66 million yuan, an increase of 30.16 million to 36.16 million yuan compared to the previous year, translating to a year-on-year growth of 101.09% to 121.20% [1]

Core Viewpoint - The company JianKai Technology forecasts a significant increase in net profit for the year 2025, driven by revenue growth from new drug clients in overseas markets [1] Financial Performance - The expected net profit attributable to the parent company for 2025 is projected to be between 60 million to 66 million yuan, representing an increase of 30.16 million to 36.16 million yuan compared to the previous year [1] - This translates to a year-on-year growth of approximately 101.09% to 121.2% [1] - The company's operating revenue is anticipated to grow by 38.71% year-on-year [1] Profitability Metrics - The net profit attributable to the parent company, excluding non-recurring gains and losses, is expected to increase by 131.01% to 156.68% year-on-year [1] - The growth in profit is primarily attributed to increased order revenue from the sales of new drug products launched by overseas clients [1]

证券代码：688356 证券简称：键凯科技 公告编号：2026-003 北京键凯科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本期业绩预告情况 （一）业绩预告期间 1 北京键凯科技股份有限公司（以下简称"公司"）预计 2025 年年度实现 营业收入约 31,500 万元，与上年同期相比，将增加 8,790.32 万元，同 比增加 38.71%。 预计 2025 年年度实现归属于母公司所有者的净利润为 6,000 万元至 6,600 万元，与上年同期相比，将增加 3,016.22 万元至 3,616.22 万元， 同比增加 101.09%至 121.20%。 预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益的净利 润为 4,500 万元至 5,000 万元，与上年同期相比，将增加 2,552.02 万 元至 3,052.02 万元，同比增加 131.01%至 156.68%。 2.预计 2025 年年度实现归属于母公司所有者的净利润为 6,000 ...

2025年度，公司营业收入预计同比增长38.71%，归属于母公司所有者的净利润预计同比增加101.09%至 121.20%，归属于母公司所有者的扣除非经常性损益的净利润预计同比增加131.01%至156.68%，主要得 益于下游海外新药客户产品上市后销售放量带来的订单收入增长以及对应的利润增长。 格隆汇1月22日丨键凯科技(688356.SH)公布，公司预计2025年年度实现营业收入约31,500万元，同比增 加38.71%。预计2025年年度实现归属于母公司所有者的净利润为6,000万元至6,600万元，同比增加 101.09%至121.20%。预计2025年年度实现归属于母公司所有者的扣除非经常性损益的净利润为4,500万 元至5,000万元，同比增加131.01%至156.68%。 ...

键凯科技1月22日公告，北京键凯科技股份有限公司预计2025年年度实现营业收入约31,500万元，与上 年同期相比，将增加8,790.32万元，同比增加38.71%。预计2025年年度实现归属于母公司所有者的净利 润为6,000万元至6,600万元，与上年同期相比，将增加3,016.22万元至3,616.22万元，同比增加101.09% 至121.20%。 ...

人民财讯1月22日电，键凯科技(688356)1月22日公告，公司预计2025年度实现归母净利润6000万元至 6600万元，同比增长101.09%至121.2%。本期业绩增长主要得益于下游海外新药客户产品上市后销售放 量带来的订单收入增长以及对应的利润增长。 ...

键凯科技公告称，预计2025年实现营收约3.15亿元，同比增加38.71%；归母净利润6000万元至6600万 元，同比增加101.09%至121.20%；扣非净利润4500万元至5000万元，同比增加131.01%至156.68%。业 绩增长得益于下游海外新药客户产品上市后销售放量带来的订单和利润增长。本次业绩预告未经审计， 具体数据以2025年年报为准。 ...